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Abstract

NIH-PA Author Manuscript

Prostaglandin E2 (PGE2) is reported to play an important role in tumor development. We explored
the differential expression of genes governing production of, and response to, PGE2 during
development of invasive bladder cancer. N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) or vehicletreated mice (n = 4–5) were euthanized after 4–8 weeks (period 1, P1), 12–16 weeks (P2), and 20–
23 weeks (P3). Half of each bladder was analyzed histologically and the other half extracted for
mRNA analysis by quantitative real-time PCR. Bladders from BBN-treated mice showed progression
from submucosal inflammation (P1) to squamous metaplasia/focal CIS (P2) to poorly differentiated,
invasive cancer (P3). mRNA levels for the inducible cyclooxygenase, COX-2, were elevated three
to fourfold at all time points in BBN-treated mice compared to controls. In contrast, mRNA levels
for constitutive COX-1 and cytosolic phospholipase A2 (cPLA2), which releases substrate for COX,
were either unchanged or decreased in BBN-treated mice relative to controls. Downstream of COX,
mRNA levels of membrane-bound PGE2 synthase (mPGES-1) were increased 1.7-fold at P1 in BBN
bladders but returned to control levels at P2 and P3. mRNA levels for 15-prostaglandin
dehydrogenase (PGDH), which inactivates PGE2, were reduced 50–80% in BBN-treated bladders at
all time points. mRNA levels for EP2R and EP4R, receptors for PGE2, were two to threefold increased
at P1, but returned to control levels or below at P3. Hence, increased COX-2 and decreased PDGH
expression occurred throughout tumor development, while mPGES-1, EP2R and EP4R were elevated
only before development of invasive cancer. We compared expression of these genes in the malignant
human urothelial cell lines, HTB-5 and HT-1376, with expression in a benign urothelial cell line,
UROtsa. Neither malignant cell line reproduced the complete in vivo pattern, relative to benign cells,
but each showed abnormal basal expression of several of the genes downstream of COX-2, but not
COX-2 itself. We conclude that components involved in PGE2 synthesis and activity are differentially
regulated during bladder tumor development and the therapeutic efficacy of targeting the various
components may vary with stage of tumor development.
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1. Introduction
Bladder cancer is the fourth most common solid malignancy in men and the ninth most common
in women, representing 7% and 3% of all cancers, respectively. In 2008 there will be an
estimated 68,810 new cases with 14,100 deaths [1]. Bladder cancer almost never presents as
an incidental finding at autopsy, indicating that at some point during the natural history of the
tumor it manifests clinically. Stage at diagnosis is fundamental to outcome. High-grade or
muscle invasive tumors tend to progress and metastasize with up to 50% of muscle invasive
tumors having occult metastatic disease at the time of diagnosis. Invasive and/or metastatic
disease carries a relatively poor prognosis with 50% of those with metastatic disease dying
within 2 years of diagnosis. Five-year survival rates are as low as 6%. There are no feasible
tumor markers capable of stratifying bladder cancer patients with regard to progression,
prognosis or treatment. Current therapies for advanced disease are disappointing. Even with
aggressive surgical and medical treatment most patients with advanced bladder cancer
ultimately succumb to their disease.
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Prostaglandins (PGs) and inducible cyclooxygenase-2 (COX-2) have been implicated in the
pathogenesis of many tumors including bladder. COX-2 is overexpressed in bladder cancer
[2–7], and a polymorphism in the NFkB-binding region of the COX-2 promoter was shown to
be associated with an increased risk of bladder cancer [8]. Overexpression of COX-2 is also
found in bladder cancer that develops in N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN)treated mice and treatment with both non-selective (indomethacin) and selective (Celecoxib)
COX inhibitors was shown to inhibit tumor development [3,9,10]. Arguments for COX-2
selective inhibitors in the prevention and treatment of bladder cancer have been summarized
in a recent review [11]. Although inhibition of COX-2 activity with selective NSAIDs has been
the most common approach to inhibiting the PG pathway, there are other potential targets (Fig.
1), such as cPLA2, which releases arachodonic acid (AA) from cell membranes to be acted on
by COX. Prostaglandin dehydrogenase (PGDH), which degrades PGE2, has recently been
implicated in multiple types of cancer as well [12,13]. Given the concerns about the safety of
long-term inhibition of COX-2 activity, selective targeting of individual PGE2 receptors is also
being considered [14].
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We explored the expression of the components of the PG pathway during development of highgrade invasive bladder cancer in a BBN murine model. In addition, we examined the expression
of these components in an immortalized benign urothelial (UROtsa) and two high-grade
bladder cancer (HTB-5, HT-1376) cell lines at basal conditions.

2. Materials and methods
2.1. BBN animal model
All animal protocols were approved by the University of Connecticut Center for Laboratory
Animal Care. Five-month-old male mice in a C57Bl/6 background were started on BBN 0.05%
in water (treatment) or water only (control). BBN is an N-nitrosamine compound whose
metabolites are known to cause bladder cancer. These cause a significant inflammatory reaction
in the bladder and also lead to similar genetic alterations as seen in human disease. There were
12 control and 13-treated mice. Two mice from each group were euthanized at 4, 8, 12, 16 and
20 weeks after starting treatment. The last mice were euthanized at 23 weeks, 1 week earlier
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than planned, due to the presence of carcinoma in the 20-week group. At 23 weeks there were
three mice in the treated group and two in the control group.
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2.2. Bladder pathology
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Bladders were halved along the midline saggital plane and then each half was sectioned into
three levels (inner, mid, outer) at 250 μm intervals. If a tumor was identified on gross inspection,
bladders were halved to include a portion of tumor. Three-micron sections from each level
were stained with H&E and all sections examined for tumor. Characteristics such as number
of cell layers, nuclear size, nuclear membrane irregularity, chromatin pattern,
nuclear:cytoplasmic ratio, presence of nucleoli and mitosis were evaluated in order to provide
a final diagnosis. Diagnoses were: (1) normal: 3–7 cell layers with normal maturation from
basal to luminal levels which includes large/flat umbrella cells; (2) metaplasia: nontransitional
appearance with squamous changes but no atypia; (3) atypia: nuclear (pleomorphism) or
architectural distortion without increased number of cells; (4) carcinoma in situ (CIS): flat
lesion within the urothelial layer displaying loss of polarity/differentiation with marked nuclear
pleomorphism, high nuclear/cytoplasmic ratio and mitotic figures; and (5) carcinoma: nodular/
sessile lesions with increased number of cells displaying characteristics as noted in CIS. The
term carcinoma is applied to all cancers since lesions showed mixed histology with both
transitional and squamous cell elements. Invasion was diagnosed if tumor cells were seen
infiltrating the muscle layers of the bladder. A single pathologist (P.H.) reviewed all slides in
a blinded fashion.
2.3. Measurement of mRNA
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Gene expression was analyzed by quantitative real time (qPCR) using RNA extracted from
half of each bladder. RNA extraction from mouse tissue has been previously described [15,
16]. In brief, tissue was homogenized in a Polytron with TRIzol® Reagent (Invitrogen Life
Technologies, Carlsbad, CA). After quantitation at 260 nm, total RNA was converted to cDNA
by ABI High Capacity cDNA Archive Kit (Applied Biosystems, Foster city, CA) following
the manufacturer’s protocol. Real-time PCR was performed for different gene expression in
separate wells (singleplex assay) of 96-well plate in reaction volume of 20 μl. GAPDH was
used as endogenous control. Two replicates of each sample were amplified using Assays-onDemand Gene Expression (Applied Biosytems, Foster City, CA), which contains predesigned
unlabeled gene-specific PCR primers and TaqMan MGB FAM dye-labeled probe. The PCR
reaction mixture (including 2X TaqMan Universal PCR Master Mix, 20X Assays-on-Demand
Gene Expression Assay Mix, 50 ng of cDNA) was run in ABI Prism 7300 Sequence Detection
System instrument utilizing universal thermal cycling parameters. For the genes for which the
efficiencies of target and endogenous control amplification were approximately equal, the
relative quantification expression in a test sample to a reference calibrator sample (ΔΔCt
Method) was used for data analysis. For the genes which were not amplified with the same
efficiency as the endogenous control, the relative standard curve method in which target
quantity is determined from the standard curve and divided by the target quantity of the
endogenous control, was used. For analysis, we grouped the samples into periods according
to time bladder pathology at time of euthanasia: period 1, 4–8 weeks; period 2, 12–16 weeks;
and period 3, 20–23 weeks. Statistical analysis of control versus treated samples was by t-test
or ANOVA where appropriate.
2.4. Cell culture
UROtsa a cells were generously donated by Dr. Brian Philips (University of Pittsburg). HTB-5
and HT-1376 cells were obtained from ATCC (Manassas, VA). All cells were grown in media
containing 100 U/ml penicillin, 50 μg/ml streptomycin and 10% fetal calf serum (FCS) in a
humidified atmosphere of 5% CO2 at 37 °C. HT-1376 cells were maintained in MEM (Eagle)
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in Earle’s BSS 90%. HTB-5 cells were maintained in MEM with Earle’s BSS, nonessential
amino acids and 1 mM sodium pyruvate 90%. UROtsa cells were maintained in DMEM without
phenol red supplemented with L-glutamine up to 1.5 nM.
For experiments, cells were plated in six-well dishes at 5 × 104 cells/ml and grown to 80%
confluence. Three separate experiments were performed. Prior to takedown serum level in the
media was reduced to 0.5% to avoid the effect of media on the induction of COX-2. RNA was
extracted, quantified and reverse transcribed as previously noted. Real-time PCR was
performed as above with GAPDH used as endogenous control. The relative standard curve
method was used for data analysis. ANOVA and a post hoc test (t-test) were used to compare
the groups.
2.5. Statistical analysis
Statistical analyses were done using SigmStat (Chicago, IL).

3. Results
3.1. Bladder pathology
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Pathologic results for the different time periods are summarized in Table 1. Pathologic findings
in our BBN model have previously been reported [17]. In brief, all bladders from control
animals have normal findings. All bladders from animals receiving BBN displayed equal
amounts of submucosal edema and inflammatory cell infiltrates (not shown). Varying degrees
of atypia and metaplasia were noted through week 12. Due to the lack of dysplastic elements,
these changes are benign in nature. Carcinoma was not noted until 16 weeks in the treatment
group. These were focal lesions representing areas of CIS (not shown). Animals euthanized at
weeks 20 and 23 showed poorly differentiated, high-grade, muscle invasive carcinoma.
3.2. Bladder gene expression
We evaluated mRNA for factors in these samples that might affect the production or action of
PGs. These included; COX-1, COX-2, cytoplasmic phospholipase A2 (cPLA2), PG synthases
1 and 2 (PGES-1, PGES-2), PG receptors EP2 and EP4 and PGDH (Fig. 1). To test for
reproducibility over time in our model COX-2 levels for control bladders, which are not
expected to change with time, were evaluated from periods 1–3. Mean ± S.E. mRNA levels
calculated by qPCR relative to a calibrator pool as described in methods were 0.31 ± 0.10, 0.33
± 0.06 and 0.31 ± 0.05, respectively. Likewise, mRNA levels were analyzed in control bladders
for other factors across all time periods with very good consistency.
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COX-2 expression was three to fourfold increased in BBN-treated bladders over all time
periods (Fig. 2). PGDH expression was reduced 45–55% in treated bladders in the first 2 time
periods and 80% at period 3 when invasive tumor was present. Both have been previously
implicated in the pathogenesis of bladder cancer. COX-1 mRNA expression was not
upregulated at any timepoint and decreased 80% by the time of invasive tumor development.
Similar results were noted for cPLA2, the enzyme responsible for release of substrate for COX.
There was a progressive decrease over the course of tumor development to 50% of its original
expression level by period 3.
As expected, the synthases and receptors were increased early, and therefore might contribute
to PG production. PGES-1 was elevated approximately twofold and PGES-2 1.5-fold in period
1 and returned to baseline during periods 2 and 3. The mRNA for PG receptors EP2R and
EP4R was increased three and twofold in period 1, respectively. The levels remained elevated
in period 2 but by the time of invasive tumor were reduced 40% or were back to control levels,
respectively.
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3.3. Benign and bladder cancer cell line gene expression
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These cell lines have been used to study regulatory mechanisms involved in bladder cancer.
We compared the cancer lines to a benign urothelial line to examine the expression pattern of
genes involved in PG synthesis in attempt to identify a cell culture model that has a similar
pattern of change as seen in our animal model. Levels of COX-2, PTGES-1, EP2, EP4 and
PGDH mRNA were measured in each cell line as these were noted to change significantly at
one or more timepoints in our in vivo model (Fig. 3). Unexpectedly, COX-2 levels were
approximately 90% reduced in all three experiments in the HTB-5 cancer lines as compared
to the UROtsa cell line. In two of three experiments, COX-2 levels in HT-1376 cells were the
same as seen in UROtsa cells with one experiment showing a 40% reduction. PGDH, the
terminal enzyme for PG degradation, was 50% lower in the HTB-5 cells and twofold higher
in the HT-1376 cells when compared to UROtsa cells. Whereas PGES-1 showed as much as
a 14-fold increase in the HT-1376 cell line it was 40% less in the HTB-5 line as compared to
UROtsa cells. The receptors for PGE2 both showed significant increase in levels in the cancer
lines compared to UROtsa. EP2 was 3.6-fold and 1.6-fold higher and EP4 was 3.5-fold and
2.2-fold higher in the HTB-5 and HT-1376 lines, respectively.

4. Discussion
NIH-PA Author Manuscript

A role for PGs in cancer was first suggested by studies showing that aspirin use decreased
colorectal cancer [18]. Subsequently, studies found that COX-2, which is normally expressed
at low levels until induced, is overexpressed in colon adenocarcinomas as well as many other
types of tumors including breast, gastric, pancreatic and prostate [19–24]. Additional studies
have demonstrated inhibitory effects of COX-2 selective NSAIDs on carcinogenesis [25–27].
An initial clinical trial examining the use of the COX-2-specific inhibitor Celecoxib in the
prevention of colon cancer reported significant reduction in the number of colon polyps in
patients with familial adenomatous polyposis (FAP) and led to FDA approval for this use
[28]. Based in part on these results, clinical trials using Celecoxib to prevent many other cancer
types including bladder, breast, cervical, colorectal, esophageal, head and neck, skin, lung, oral
and prostate cancers as well as multiple myeloma were initiated. However, concern was raised
regarding the long-term use of COX-2 inhibitors after the report of a twofold increased risk of
cardiovascular events in patients taking the COX-2 inhibitor rofecoxib in a colon adenoma
prevention trial [29].
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Although inhibition of COX-2 activity and subsequent PG production with selective NSAIDs
has been the most common approach to inhibiting the PG pathway, other potential targets exist.
Early studies have shown promise at varying points along the pathway of PG production to
receptors and degrading enzymes (Fig. 1). Downregulation of cPLA2 has been reported to lead
to growth inhibition and apoptosis in colon cancer cells [30]. Selective targeting of individual
PGE2 receptors is also being explored in a model of hormone-refractory, metastatic breast
cancer [14]. Additionally, decreased levels of PGDH, which degrades PGE2, has recently been
implicated in colon cancer and has been reported in high-grade bladder cancer [12,13,31]. We
sought to characterize the role of components of the PG pathway in a model covering the timecourse of progression from dysplasia through high-grade, invasive bladder cancer. In addition,
we evaluated the expression of these factors in cell lines representing benign and high-grade
disease in attempt to identify a viable model for exploration of mechanisms involved.
In our study the components of the pathway involved in PG production showed variable
expression during the timecourse of development of invasive cancer. Two genes, COX-2 and
PGDH, were consistently different than control throughout the study. COX-2 was elevated and
PGDH was decreased, both consistent with increased PGs. Both have been previously reported
to be involved in the development of bladder cancer. Consistent with previous studies, our data
indicate that elevated expression of COX-2 might be involved in the pathogenesis of bladder
Prostaglandins Other Lipid Mediat. Author manuscript; available in PMC 2010 January 1.
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cancer in the BBN model [3,9,10]. COX-2 mRNA levels were increased threefold at the earliest
timepoint and remained essentially unchanged through development of invasive cancer. A
recent study has reported a progressive increase in the protein expression of COX-2 by
immunohistochemistry (IHC) in tissue from normal urothelium to invasive and metastatic
disease [32]. An important difference between the studies is that they examined protein
expression, whereas we evaluated mRNA levels. It is possible that there may in fact be
increased expression of COX-2 in tumor cells in our model however this may have been lost
in sampling which included adjacent tissue with high levels of inflammation. Future studies
could utilize in situ hybridization or laser capture microdissection to determine the exact cells
in which COX-2 mRNA expression is increased. PGDH levels decrease progressively over the
development of cancer. This reciprocal drop in PGDH at the time of COX-2 elevation has been
reported recently in lung cancer tissue [33]. Additionally, evaluation of PGDH in bladder
cancer specimens reported a significant correlation between the degree of
immunohistochemical staining for PGDH with tumor stage and grade [31]. Decreased staining
was associated with higher stage/grade tumors. The above would suggest that the impact of
change occurs early and inhibition would therefore also need to be early in the development
of tumor.
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COX-1 levels decreased throughout the course of the study. cPLA2 levels were also decreased
at the time of invasive disease. It is possible that these represent a negative feedback from the
presumed production of PGs which would be present with the sustained elevation of COX-2
and decrease in PGDH. One other study reported elevated cPLA2 levels at the time of cancer
presence in a rat model of bladder cancer but did not comment on the stage or grade of tumor
[34]. Bladder cancer is known to exhibit two distinct phenotypes, low-grade and high-grade,
which have distinct genetic and epigenetic alterations as well as clinical courses [35]. Treatment
of rats with BBN is known to cause papillomas and low-grade disease, whereas the BBN model
in mice causes high-grade invasive tumors which could potentially account for these
differences.
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As expected both the synthases and receptors for PGs were increased early. Although the
synthases showed early increases they returned to baseline levels by the time of tumor
development which could also be in response to elevated PGs. Increased mPGES-1 and normal
mPGES-2 levels have been reported in bladder cancer in rats [34] and increased mPGES-1
levels noted in precancerous skin lesions [36]. Our data would be consistent with these findings
in that elevated mPGES-1 was noted during the time of inflammation and dysplasia and
mPGES-2 was not seen to be elevated in the presence of cancer. We chose to evaluate two of
the four receptors based on prior literature indicating potential roles for EP2 and EP4 in cancer
[36,37]. Increased PG receptor levels would indicate increased sensitivity to PG. We found the
expression of EP2 to be markedly elevated at the time of predominant inflammation and EP4
levels to be elevated through early cancer presentation (CIS). In both cases the levels gradually
declined to basal or lower levels as invasive cancer developed. Contrary to our study, PG
receptor levels have been reported to increase across the spectrum of normal to adenoma to
adenocarcinoma in colon (EP4) [37] and be increased in skin papillomas (EP2) [36]. It is
possible that this represents a response to the sustained presence of inflammation and increase
in COX-2 and presumed PG production in our model.
Our cell culture model displayed high variability with regard to expression levels of the
components of PG synthesis. Contrary to prior studies that reported high levels of COX-2
expression in malignant urothelial cell lines [38,39], we saw a statistically significant reduction
in COX-2 expression in the cancer lines compared to the benign UROtsa cells. One difference
between these studies and ours which may account for this disparity is the use of a benign cell
line. The studies noted above did not use such a line for comparison. However, in agreement
with these studies we found the level of expression to be highly variable across the lines.
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Conversely, the PG receptor levels were found to be significantly higher in the cancer cells as
was the synthase in at least one of the cell lines (HT-1376). PGDH was noted to be highest in
this line as well. Overall we did not see a trend in expression when comparing the benign to
cancer cells. The variability seen in our study as well as others would suggest that in vitro
models of PG production in bladder cancer cell lines are less reliable than an in vivo model of
de novo cancer development. The latter would also allow for study of the impact of selective
inhibitor use or specific gene deletion.
Our study confirms prior observations made regarding elements of the PG pathway in other
cancers at static levels of tumor development. However, our report suggested that there is
differential regulation of the components involved in PG synthesis and activity during bladder
tumor development and that the therapeutic efficacy of targeting the various components will
vary with stage of tumor development. Cell culture modeling does not appear to be as reliable
a method of study of the role of the PG pathway given the high variability of component
expression between benign and cancer cell lines.
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Fig. 1.

PG pathway.
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Fig. 2.

Prostaglandin pathway gene expression by qPCR in BBN mouse model of bladder cancer.
Black bars are means ± S.E. for n = 4 control bladders. Gray bars are means ± S.D. for n = 3–
4 BBN-treated bladders. aSignificant difference relative to control at same period, P <
0.01; bP < 0.05.
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Fig. 3.

Prostaglandin pathway gene expression by qPCR in benign (UROtsa) and malignant (HTB-5,
HT-1376) cell lines. All differences between cancer cell lines and UROtsa are statistically
significant (p < 0.05). RQ = relative quantification.
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Table 1

Pathologic diagnosis in mice treated with BBN.
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Period

Pathologic diagnosis of BBN-treated mice

1 (Weeks 4–8)

Atypia (n = 4/4)

2 (Weeks 12–16)

Squamous metaplasia (n = 3/4) Focal CIS (n = 1/4)

3 (Weeks 20–23)

Invasive carcinoma (n = 5/5)

There were two mice in each group (except for week 23, which had five). Diagnosis represents most significant findings.
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